Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (Nasdaq: CAPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases. Its lead candidate, Deramiocel, is in Phase 3 clinical trials. The company has no approved commercial products and relies on equity financing and collaboration payments for operations.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Net Loss | $(24.6) million | $(74.9) million | — |
| Operating Expenses | $(26.3) million | $(79.0) million | — |
| Cash & Cash Equivalents | — | — | $19.5 million |
| Marketable Securities | — | — | $79.1 million |
| Total Liquidity | — | — | $98.6 million |
| Accumulated Deficit | — | — | $(274.7) million |
| Working Capital | — | — | $72.8 million |
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for the three and nine months ended September 30, 2025, compared to $2.3 million and $11.1 million in the same periods of 2024. The prior year revenue was derived from milestone payments and proportional performance recognition under the U.S. Distribution Agreement with Nippon Shinyaku, which has now been fully recognized.
- Net Loss: Net loss increased significantly to $24.6 million (Q3 2025) and $74.9 million (9M 2025) from $12.6 million and $33.4 million in the prior year periods, respectively.
- Operating Expenses:
- R&D Expenses: Increased 72% in Q3 and 73% in the nine-month period year-over-year. This was driven by increased headcount, expanded manufacturing production for Deramiocel, and costs associated with the HOPE-3 clinical trial and exosome platform research.
- G&A Expenses: Increased 71% in Q3 and 67% in the nine-month period year-over-year, primarily due to higher personnel costs, professional fees (legal/consulting), and stock-based compensation.
- Liquidity: Total cash, cash equivalents, and marketable securities decreased from $151.5 million at December 31, 2024, to $98.6 million at September 30, 2025, reflecting continued operational burn and capital expenditures.
Guidance, Outlook, Risks, and Contingencies
- Regulatory Status (Deramiocel): In July 2025, the FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA), stating that additional clinical data was required. The FDA agreed that the ongoing HOPE-3 Phase 3 trial would serve as the additional study. Topline data is expected in Q4 2025. The company plans to resubmit the BLA with HOPE-3 data.
- Exosome Platform: A Phase 1 clinical trial for the StealthX vaccine (in collaboration with NIAID) initiated in August 2025. Initial data is expected in Q1 2026.
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date. Current cash resources are insufficient to fund operations without additional financing.
- Financing Plans: The company established a new At-The-Market (ATM) program in September 2025 for up to $150 million. No shares have been sold under this program to date. The company may seek additional equity or debt financing, which could result in dilution.
- Legal Contingencies:
- A putative securities class action was filed in July 2025 alleging violations of federal securities laws.
- A derivative action was filed in August 2025 alleging breaches of fiduciary duties.
- A Section 220 Shareholder Demand Letter was received in October 2025 regarding inspection of books and records.
- CIRM Loan Conversion: The company elected to convert a $3.4 million CIRM grant into a loan. Accrued interest could reach up to $7.9 million depending on final terms.
Investor Verification Checklist
- HOPE-3 Trial Results: Verify the timing and outcome of the top-line data release for the HOPE-3 Phase 3 trial, which is critical for BLA resubmission.
- Capital Raise Execution: Monitor the utilization of the new $150 million ATM program and any other equity/debt financing announcements to address the going concern warning.
- Legal Proceedings: Track the status of the securities class action, derivative suit, and shareholder demand letter for potential financial impact or management distraction.
- Manufacturing Readiness: Confirm the status of the San Diego GMP facility and inventory buildout for potential commercial launch, given the recent FDA Form 483 observations (which were resolved).
- European Partnership: Monitor the negotiation status of the Binding Term Sheet with Nippon Shinyaku for the European region, with a negotiation deadline of November 30, 2025.